Brand-specific estimates of influenza vaccine effectiveness for the 2021-2022 season in Europe: results from the DRIVE multi-stakeholder study platform

Introduction: Development of Robust and Innovative Vaccine Effectiveness (DRIVE) was a European public-private partnership (PPP) that aimed to provide annual, brand-specific estimates of influenza vaccine effectiveness (IVE) for regulatory and public health purposes. DRIVE was launched in 2017 under...

Descripción completa

Detalles Bibliográficos
Autores: Stuurman, A.L., Carmona, A., Biccler, J., Descamps, A., Levi, M., Baum, U., Mira-Iglesias, A., Bellino, S., Hoang, U., Lusignan, S.D., Bonaiuti, R., Lina, B., Rizzo, C., Nohynek, H., Diez Domingo, Javier
Tipo de recurso: artículo
Fecha de publicación:2023
País:España
Institución:Servizo Galego de Saúde (SERGAS)
Repositorio:RUNA. Repositorio da Consellería de Sanidade e Sergas
OAI Identifier:oai:runa.sergas.gal:20.500.11940/21166
Acceso en línea:https://portalcientifico.sergas.gal//documentos/64ec7b6ae13d1f2d6d3b7072
http://hdl.handle.net/20.500.11940/21166
Access Level:acceso abierto
Palabra clave:Adult
Aged
Child
Humans
Cohort Studies
COVID-19
COVID-19 Vaccines
Europe
Influenza Vaccines
Influenza, Human
Seasons
Vaccine Efficacy
Male
Female
Adolescent
Young Adult
Middle Aged
AS Santiago
IDIS
id ES_051aad6bafc06d71ee299727f458bf90
oai_identifier_str oai:runa.sergas.gal:20.500.11940/21166
network_acronym_str ES
network_name_str España
repository_id_str
spelling Brand-specific estimates of influenza vaccine effectiveness for the 2021-2022 season in Europe: results from the DRIVE multi-stakeholder study platformStuurman, A.L.Carmona, A.Biccler, J.Descamps, A.Levi, M.Baum, U.Mira-Iglesias, A.Bellino, S.Hoang, U.Lusignan, S.D.Bonaiuti, R.Lina, B.Rizzo, C.Nohynek, H.Diez Domingo, JavierAdultAgedChildHumansCohort StudiesCOVID-19COVID-19 VaccinesEuropeInfluenza VaccinesInfluenza, HumanSeasonsVaccine EfficacyMaleFemaleAdolescentYoung AdultMiddle AgedAS SantiagoIDISIntroduction: Development of Robust and Innovative Vaccine Effectiveness (DRIVE) was a European public-private partnership (PPP) that aimed to provide annual, brand-specific estimates of influenza vaccine effectiveness (IVE) for regulatory and public health purposes. DRIVE was launched in 2017 under the umbrella of the Innovative Medicines Initiative (IMI) and conducted IVE studies from its pilot season in 2017-2018 to its final season in 2021-2022. Methods: In 2021-2022, DRIVE conducted four primary care-based test-negative design (TND) studies (Austria, Italy, Iceland, and England; involving >1,000 general practitioners), nine hospital-based TND studies (France, Iceland, Italy, Romania, and Spain, for a total of 21 hospitals), and one population-based cohort study in Finland. In the TND studies, patients with influenza-like illness (primary care) or severe acute respiratory infection (hospital) were enrolled, and laboratory tested for influenza using RT-PCR. Study contributor-specific IVE was calculated using logistic regression, adjusting for age, sex, and calendar time, and pooled by meta-analysis. Results: In 2021-2022, pooled confounder-adjusted influenza vaccine effectiveness (IVE) estimates against laboratory-confirmed influenza (LCI) overall and per type and subtype/lineage was produced, albeit with wide confidence intervals (CI). The limited circulation of influenza in Europe did not allow the network to reach the optimal sample size to produce precise IVE estimates for all the brands included. The most significant IVE estimates were 76% (95% CI 23%?93%) for any vaccine and 81% (22%?95%) for Vaxigrip Tetra in adults ?65 years old and 64% (25%?83%) for Fluenz Tetra in children (TND primary care setting), 85% (12%?97%) for any vaccine in adults 18-64 years (TND hospital setting), and 38% (1%?62%) in children 6 months?6 years (population-based cohort, mixed setting). Discussion: Over five seasons, DRIVE collected data on >35,000 patients, more than 60 variables, and 13 influenza vaccines. DRIVE demonstrated that estimating brand-specific IVE across Europe is possible, but achieving sufficient sample size to obtain precise estimates for all relevant stratifications remains a challenge. Finally, DRIVE's network of study contributors and lessons learned have greatly contributed to the development of the COVID-19 vaccine effectiveness platform COVIDRIVE.Funding The DRIVE project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No. 777363); this Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation program and EFPIA.2023info:eu-repo/semantics/articlehttps://portalcientifico.sergas.gal//documentos/64ec7b6ae13d1f2d6d3b7072http://hdl.handle.net/20.500.11940/21166reponame:RUNA. Repositorio da Consellería de Sanidade e Sergasinstname:Servizo Galego de Saúde (SERGAS)Ingléshttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:runa.sergas.gal:20.500.11940/211662026-06-12T08:40:47Z
dc.title.none.fl_str_mv Brand-specific estimates of influenza vaccine effectiveness for the 2021-2022 season in Europe: results from the DRIVE multi-stakeholder study platform
title Brand-specific estimates of influenza vaccine effectiveness for the 2021-2022 season in Europe: results from the DRIVE multi-stakeholder study platform
spellingShingle Brand-specific estimates of influenza vaccine effectiveness for the 2021-2022 season in Europe: results from the DRIVE multi-stakeholder study platform
Stuurman, A.L.
Adult
Aged
Child
Humans
Cohort Studies
COVID-19
COVID-19 Vaccines
Europe
Influenza Vaccines
Influenza, Human
Seasons
Vaccine Efficacy
Male
Female
Adolescent
Young Adult
Middle Aged
AS Santiago
IDIS
title_short Brand-specific estimates of influenza vaccine effectiveness for the 2021-2022 season in Europe: results from the DRIVE multi-stakeholder study platform
title_full Brand-specific estimates of influenza vaccine effectiveness for the 2021-2022 season in Europe: results from the DRIVE multi-stakeholder study platform
title_fullStr Brand-specific estimates of influenza vaccine effectiveness for the 2021-2022 season in Europe: results from the DRIVE multi-stakeholder study platform
title_full_unstemmed Brand-specific estimates of influenza vaccine effectiveness for the 2021-2022 season in Europe: results from the DRIVE multi-stakeholder study platform
title_sort Brand-specific estimates of influenza vaccine effectiveness for the 2021-2022 season in Europe: results from the DRIVE multi-stakeholder study platform
dc.creator.none.fl_str_mv Stuurman, A.L.
Carmona, A.
Biccler, J.
Descamps, A.
Levi, M.
Baum, U.
Mira-Iglesias, A.
Bellino, S.
Hoang, U.
Lusignan, S.D.
Bonaiuti, R.
Lina, B.
Rizzo, C.
Nohynek, H.
Diez Domingo, Javier
author Stuurman, A.L.
author_facet Stuurman, A.L.
Carmona, A.
Biccler, J.
Descamps, A.
Levi, M.
Baum, U.
Mira-Iglesias, A.
Bellino, S.
Hoang, U.
Lusignan, S.D.
Bonaiuti, R.
Lina, B.
Rizzo, C.
Nohynek, H.
Diez Domingo, Javier
author_role author
author2 Carmona, A.
Biccler, J.
Descamps, A.
Levi, M.
Baum, U.
Mira-Iglesias, A.
Bellino, S.
Hoang, U.
Lusignan, S.D.
Bonaiuti, R.
Lina, B.
Rizzo, C.
Nohynek, H.
Diez Domingo, Javier
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Adult
Aged
Child
Humans
Cohort Studies
COVID-19
COVID-19 Vaccines
Europe
Influenza Vaccines
Influenza, Human
Seasons
Vaccine Efficacy
Male
Female
Adolescent
Young Adult
Middle Aged
AS Santiago
IDIS
topic Adult
Aged
Child
Humans
Cohort Studies
COVID-19
COVID-19 Vaccines
Europe
Influenza Vaccines
Influenza, Human
Seasons
Vaccine Efficacy
Male
Female
Adolescent
Young Adult
Middle Aged
AS Santiago
IDIS
description Introduction: Development of Robust and Innovative Vaccine Effectiveness (DRIVE) was a European public-private partnership (PPP) that aimed to provide annual, brand-specific estimates of influenza vaccine effectiveness (IVE) for regulatory and public health purposes. DRIVE was launched in 2017 under the umbrella of the Innovative Medicines Initiative (IMI) and conducted IVE studies from its pilot season in 2017-2018 to its final season in 2021-2022. Methods: In 2021-2022, DRIVE conducted four primary care-based test-negative design (TND) studies (Austria, Italy, Iceland, and England; involving >1,000 general practitioners), nine hospital-based TND studies (France, Iceland, Italy, Romania, and Spain, for a total of 21 hospitals), and one population-based cohort study in Finland. In the TND studies, patients with influenza-like illness (primary care) or severe acute respiratory infection (hospital) were enrolled, and laboratory tested for influenza using RT-PCR. Study contributor-specific IVE was calculated using logistic regression, adjusting for age, sex, and calendar time, and pooled by meta-analysis. Results: In 2021-2022, pooled confounder-adjusted influenza vaccine effectiveness (IVE) estimates against laboratory-confirmed influenza (LCI) overall and per type and subtype/lineage was produced, albeit with wide confidence intervals (CI). The limited circulation of influenza in Europe did not allow the network to reach the optimal sample size to produce precise IVE estimates for all the brands included. The most significant IVE estimates were 76% (95% CI 23%?93%) for any vaccine and 81% (22%?95%) for Vaxigrip Tetra in adults ?65 years old and 64% (25%?83%) for Fluenz Tetra in children (TND primary care setting), 85% (12%?97%) for any vaccine in adults 18-64 years (TND hospital setting), and 38% (1%?62%) in children 6 months?6 years (population-based cohort, mixed setting). Discussion: Over five seasons, DRIVE collected data on >35,000 patients, more than 60 variables, and 13 influenza vaccines. DRIVE demonstrated that estimating brand-specific IVE across Europe is possible, but achieving sufficient sample size to obtain precise estimates for all relevant stratifications remains a challenge. Finally, DRIVE's network of study contributors and lessons learned have greatly contributed to the development of the COVID-19 vaccine effectiveness platform COVIDRIVE.
publishDate 2023
dc.date.none.fl_str_mv 2023
dc.type.none.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://portalcientifico.sergas.gal//documentos/64ec7b6ae13d1f2d6d3b7072
http://hdl.handle.net/20.500.11940/21166
url https://portalcientifico.sergas.gal//documentos/64ec7b6ae13d1f2d6d3b7072
http://hdl.handle.net/20.500.11940/21166
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv http://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.source.none.fl_str_mv reponame:RUNA. Repositorio da Consellería de Sanidade e Sergas
instname:Servizo Galego de Saúde (SERGAS)
instname_str Servizo Galego de Saúde (SERGAS)
reponame_str RUNA. Repositorio da Consellería de Sanidade e Sergas
collection RUNA. Repositorio da Consellería de Sanidade e Sergas
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869402834248663040
score 15,811543

Similares en LA Referencia